Center for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Department of Medicine, University of Padova, Padova, Italy.
Nat Rev Nephrol. 2021 Jul;17(7):493-502. doi: 10.1038/s41581-021-00410-w. Epub 2021 Mar 12.
Over the past decade, new insights into epidemiology, pathophysiology and biomarkers have modified our understanding of acute kidney dysfunction and damage, and their association with subsequent chronic kidney disease. The concept of acute kidney injury (AKI), which has relied on established but nonetheless flawed biomarkers of solute clearance (serum creatinine levels and urinary output), has been challenged by the identification of novel biomarkers of tubular stress and/or damage. The expression of some of these novel biomarkers precedes changes in conventional biomarkers or can increase their predictive power, and might therefore enhance the clinical accuracy of the definition of AKI. In addition, the need to consider AKI recurrence, duration and progression to chronic kidney disease within the clinical and epidemiological framework of AKI led to the emergence of the concept of acute kidney disease. New definitions of acute syndromes of kidney impairment and injury are needed.
在过去的十年中,对流行病学、病理生理学和生物标志物的新认识改变了我们对急性肾功能障碍和损伤及其与随后发生的慢性肾脏病之间关系的理解。急性肾损伤(AKI)的概念依赖于已建立但仍然有缺陷的溶质清除(血清肌酐水平和尿量)生物标志物,这一概念受到了新型肾小管应激和/或损伤生物标志物的挑战。其中一些新型生物标志物的表达先于传统生物标志物的变化,或者可以提高其预测能力,因此可以提高 AKI 定义的临床准确性。此外,需要在 AKI 的临床和流行病学框架内考虑 AKI 的复发、持续时间和进展为慢性肾脏病,这导致了急性肾脏病概念的出现。需要新的急性肾损伤和损伤综合征的定义。